Vasohibin-1 Increases Paclitaxel Sensitivity in Ovarian Cancer
Author Information
Author(s): Koyanagi Takahiro, Saga Yasushi, Takahashi Yoshifumi, Tamura Kohei, Takahashi Suzuyo, Taneichi Akiyo, Takei Yuji, Mizukami Hiroaki, Fujiwara Hiroyuki
Primary Institution: Jichi Medical University
Hypothesis
Does forced expression of Vasohibin-1 enhance paclitaxel sensitivity in ovarian cancer cells?
Conclusion
Vasohibin-1 overexpression enhances paclitaxel sensitivity in ovarian cancer cells by affecting microtubule activity.
Supporting Evidence
- VASH1 overexpression increased detyrosinated tubulin and cyclin B1 expression.
- Paclitaxel chemosensitivity was significantly enhanced in VASH1-overexpressing cells compared to control cells.
- No significant difference in chemosensitivity to cisplatin was observed.
Takeaway
When scientists increased the amount of a protein called Vasohibin-1 in ovarian cancer cells, those cells became much better at responding to a cancer drug called paclitaxel.
Methodology
The study used gene-transfected ovarian cancer cell lines and performed western blot analysis and WST-1 assays to assess chemosensitivity.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website